• Bank of America (NYSE:BAC) lowered its rating on Goldman Sachs (NYSE:GS) to “neutral” from “buy” and cut the price target to $160 from $230, citing today’s news of a criminal probe
• Endo Pharmaceuticals (NASDAQ:ENDP) posted a first quarter one-penny miss as earnings of 74 fell just short of Zacks estimates of 75 cents. Revenues of $364 million missed Zacks estimates of $379 million.
• Avon (NYSE:AVP) posted first quarter results off 33 cents, one cent better than expected on inline revenues of $2.5 billion
• D.R. Horton (NYSE: DHI) reported fiscal second quarter earnings of 4 cents, versus Zacks expectations of a loss of 3 cents a share, on revenues of $897 million, which topped Zacks estimates of $812 million.
• Newell Rubbermaid (NYSE:NWL) announced first quarter earnings of 25 cents, 7 cents ahead of Zacks estimates on revenues of $1.3 billion, which topped Zacks estimates of $1.21 billion
• Dendreon (NASDAQ:DNDN) received FDA clearance for its therapeutic prostate cancer vaccine “Provenge”
• Aetna (NYSE:AET) reported first quarter results five cents more than projected at 77 cents on revenues of $8.5 billion, which were in-line with Zacks estimates of $8.5 billion
